average weight loss first week on tirzepatide Zepbound Results: Month and Beyond Where Do You Lose Weight – Tirzepatide Before and After Results:

Eli Lilly: The Challenger with a Dual-Action Advantage Pharma giant Eli Lilly has shaken up the anti-obesity drug market with tirzepatide branded as MOUNJARO for diabetes and ZEPBOUND for obesity

Digestive symptoms are the most common early side effects

These medications, originally developed to treat diabetes and support weight management, have been linked to severe gastrointestinal injuries, stomach paralysis, vision loss, and other serious health complications

"Many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," Patrik Jonsson, president of Lilly Cardiometabolic Health, said in a news release from the company